Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy as a Treatment for Glioblastoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-10-01

Study Completion Date

2020-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Temozolomide (TMZ) is an oral chemotherapy drug. It is an alkylating agent used as a first-line treatment for glioblastoma. This methylation damages the DNA and triggers the death of tumor cells. According to the results of several clinical studies, TMZ synchronous plus radiotherapy and subsequent as adjuvant therapy can significantly improve the survival rate of newly diagnosed glioblastoma patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed GBM Multiforme

NCT05600491

Anaplastic Oligoastrocytoma Glioblastoma

RECRUITING PHASE3

Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma

NCT06279767

Glioblastoma Cancer Temozolomide

RECRUITING PHASE1/PHASE2

Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

NCT00304031

Brain and Central Nervous System Tumors

COMPLETED PHASE3

Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas

NCT01670890

Malignant Gliomas

UNKNOWN PHASE2

Temozolomide Chronotherapy for High Grade Glioma

NCT02781792

Glioma Glioblastoma Multiforme

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Glioma is the highest incidence of the central nervous system tumor. Surgical treatment is one of the most important therapeutic methods in patients with glioblastoma. But since malignant glioma is a highly invasive tumor, the rate of surgery failure is . So the postoperative therapy shall be accompanied by radiotherapy. Since 1998, the clinical application of Temozolomide(TMZ) has brought hope for malignant glioma patients with its definite curative effect. According to the results of several clinical studies, TMZ synchronous plus radiotherapy and subsequent as adjuvant therapy can significantly improve the survival rate of newly diagnosed GBM patients and break the survival limit of malignant glioma patients. Besides, antiangiogenic therapy is also a choice for the treatment of glioblastoma patients. Vascular endothelial growth factor receptors (VEGFRs) inhibitors block the new formation around the tumor and cut down the supply of oxygen, nutrients and metabolic waste, so that the tumor is hard to proliferate and metastases.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioblastoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental 1

concurrent chemoradiotherapy（Temozolomide+apatinib） maintenance therapy（Temozolomide）

Apatinib

Intervention Type DRUG

These drugs are planned to inhibit the proliferation and metastasis of tumors.

Temozolomide（TMZ）

Intervention Type DRUG

Radiotherapy is a common treatment for glioblastoma.Accompanied with TMZ, the damages caused by tumors to the normal tissues will be reduced.

control

concurrent chemoradiotherapy（Temozolomide） maintenance therapy（Temozolomide）

Temozolomide（TMZ）

Intervention Type DRUG

Radiotherapy is a common treatment for glioblastoma.Accompanied with TMZ, the damages caused by tumors to the normal tissues will be reduced.

Experimental 2

concurrent chemoradiotherapy（Temozolomide+apatinib） maintenance therapy（Temozolomide+apatinib）

Apatinib

Intervention Type DRUG

These drugs are planned to inhibit the proliferation and metastasis of tumors.

Temozolomide（TMZ）

Intervention Type DRUG

Radiotherapy is a common treatment for glioblastoma.Accompanied with TMZ, the damages caused by tumors to the normal tissues will be reduced.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Apatinib

These drugs are planned to inhibit the proliferation and metastasis of tumors.

Intervention Type DRUG

Temozolomide（TMZ）

Radiotherapy is a common treatment for glioblastoma.Accompanied with TMZ, the damages caused by tumors to the normal tissues will be reduced.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Temozolomide（TMZ）

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Search Criteria:

1. Subjects received anti-angiogenesis drugs simultaneous accompanied with radio-and chemotherapy in Fuzhou Zongyuan since October, 2017;
2. Age: 18-70 years;
3. The first surgical pathology was diagnosed as glioblastoma, WHO grade III or IV;
4. Patients who have previously received no more than one surgical treatment;
5. ECOG performance status: 0-2;
6. Survival expectation≥3 months.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No